Company news
Tempus Ai, Inc. (NASDAQ:TEM) news
Tempus Ai, Inc. news releases on 6ix. Latest, Feb 10, 2026: Tempus to Report Fourth Quarter and Full Year 2025 Financial Results on February 24
Press releases — page 2
Tempus to Report Fourth Quarter and Full Year 2025 Financial Results on February 24
February 10, 2026
Ambry’s Contributions to MAVEs Support Thousands of Patient Reclassifications and Expand to New Genes
February 3, 2026
Ambry Genetics Announces One Millionth Test Leveraging RNA to Improve Diagnostic Accuracy and Yield
February 1, 2026
Tempus Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers
January 27, 2026
Tempus Announces the Launch of Paige Predict
January 21, 2026
Tempus and NYU Langone Health Announce Strategic Collaboration to Advance Precision Oncology
January 12, 2026
Northwestern Medicine Selects Tempus to Expand Genomic Testing
January 11, 2026
Tempus Achieves Record Total Contract Value Exceeding $1.1 Billion
January 11, 2026
Tempus Announces Preliminary Fourth Quarter and Full Year 2025 Results
January 10, 2026
Tempus Announces Eight Abstracts Accepted for Presentation at the 2026 ASCO® Gastrointestinal Cancers Symposium
January 8, 2026
Tempus to Present at 44th Annual J.P. Morgan Healthcare Conference
January 5, 2026
Tempus Announces Ten Abstracts Accepted for Presentation at the 2025 San Antonio Breast Cancer Symposium
December 8, 2025
Tempus to Participate in the Piper Sandler 37th Annual Healthcare Conference
November 17, 2025
Tempus and IFLI Announce Study to Advance Follicular Lymphoma Research
November 13, 2025
Tempus Announces Six Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer Annual Meeting 2025
November 4, 2025
Tempus Reports Third Quarter 2025 Results
November 3, 2025
Tempus to Participate in the Stifel 2025 Healthcare Conference
October 27, 2025
Tempus to Report Third Quarter 2025 Financial Results on November 4
October 20, 2025
Ambry Genetics Announces 10-Year Study in Genetics in Medicine Highlighting the Impact of Proactive Exome Reanalysis for Healthcare Equity
October 19, 2025
Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research
October 15, 2025
Tempus Announces Six Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025
October 14, 2025
Tempus Selected by ARPA-H to Provide CRO and Testing Services for the ADAPT Program, Advancing Precision Cancer Therapy
October 8, 2025
Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution with Upgraded Tyrer-Cuzick Scoring Approach Incorporating Breast Density
September 30, 2025
Tempus Receives U.S. FDA 510(k) Clearance for Tempus xR IVD, its RNA NGS In Vitro Diagnostic Device
September 21, 2025
Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease
September 14, 2025
Tempus Receives U.S. FDA Special 510(k) Clearance for Updated Tempus Pixel Device
September 10, 2025
Tempus Announces New Study in JCO Precision Oncology Validating PurIST® Algorithm for Enhanced Therapy Selection in Pancreatic Cancer
September 8, 2025
Northwestern Medicine Becomes First Health System to Integrate Tempus’ Generative AI Co-Pilot, David, Into Its EHR Platform
September 3, 2025
Tempus to Participate in Morgan Stanley’s 23rd Annual Global Healthcare Conference
September 2, 2025
Tempus Announces the Acquisition of Paige
August 21, 2025
Tempus Reports Second Quarter 2025 Results
August 7, 2025
Personalis Reports Second Quarter 2025 Financial Results
August 5, 2025
Tempus to Report Second Quarter 2025 Financial Results on August 8
July 21, 2025
Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-Low EF Software
July 15, 2025
Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients
July 8, 2025
Tempus Expands AI-Enabled Care Pathway Intelligence Platform into Breast Cancer
July 7, 2025
Tempus Announces Pricing of Upsized Offering of $650 Million of Convertible Senior Notes
June 29, 2025
Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense
June 29, 2025
Ambry Genetics’ CARE Program Validated for Accuracy in Identifying High-Risk Patients for Hereditary Cancer Testing
June 24, 2025
Tempus to Participate in TD Cowen’s 4th Annual Tools/Dx Revolution Conference
June 16, 2025
Tempus Announces Collaboration with Northwestern University’s Abrams Research Center on Neurogenomics to Leverage AI for Alzheimer’s Disease Research
June 11, 2025
Tempus Introduces xM, An Assay to Monitor Immunotherapy Response for Patients with Advanced Cancers
June 1, 2025
Introducing Tempus One in the EHR with Integrated Guidelines
May 31, 2025
Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model
May 30, 2025
Tempus Announces 10 Abstracts Accepted for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting
May 29, 2025
A Decade of Discovery: Tempus Supported Almost 1,500 Research Projects in 10 Years
May 27, 2025
New Study Shows Impact of Ambry Genetics’ Patient for Life™ Program on Rare Disease Diagnosis
May 27, 2025
Tempus to Present at the William Blair 45th Annual Growth Stock Conference
May 20, 2025
Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment
May 19, 2025
Tempus Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer Pipeline
May 13, 2025